Cytek Biosciences Inc
CTKB3.840USD
+0.200+5.49%
Handelsschluss 08/04, 16:00（ET）Kurse um 15 Minuten verzögert
489.98MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über Cytek Biosciences Inc Unternehmen
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Unternehmensinformationen
BörsenkürzelCTKB
Name des UnternehmensCytek Biosciences Inc
IPO-datumJul 23, 2021
CEODr. Wenbin Jiang, Ph.D.
Anzahl der mitarbeiter648
WertpapierartOrdinary Share
GeschäftsjahresendeJul 23
Addresse47215 Lakeview Boulevard
StadtFREMONT
BörseNASDAQ Global Select Consolidated
LandUnited States of America
Postleitzahl94538
Telefon18779229835
Websitehttps://cytekbio.com
BörsenkürzelCTKB
IPO-datumJul 23, 2021
CEODr. Wenbin Jiang, Ph.D.
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.04M
+0.17%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.26M
+0.70%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
83.67K
+14.04%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Michael Holder
Michael Holder
Independent Director
Independent Director
8.00K
+22.22%
Mr. William (Bill) Mccombe
Mr. William (Bill) Mccombe
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Jack T. Ball, Jr.
Mr. Jack T. Ball, Jr.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Ming Yan, Ph.D.
Dr. Ming Yan, Ph.D.
Co-Founder, Chief Technology Officer, Director
Co-Founder, Chief Technology Officer, Director
6.04M
+0.17%
Dr. Wenbin Jiang, Ph.D.
Dr. Wenbin Jiang, Ph.D.
Chairman of the Board, President, Chief Executive Officer, Co-Founder
Chairman of the Board, President, Chief Executive Officer, Co-Founder
5.26M
+0.70%
Ms. Valerie Barnett, J.D.
Ms. Valerie Barnett, J.D.
Chief Legal Officer and Corporate Secretary
Chief Legal Officer and Corporate Secretary
83.67K
+14.04%
Dr. Philippe Busque, Ph.D.
Dr. Philippe Busque, Ph.D.
Senior Vice President, Global Sales and Services
Senior Vice President, Global Sales and Services
18.92K
+18.83%
Ms. Deborah J. Neff
Ms. Deborah J. Neff
Lead Independent Director
Lead Independent Director
15.71K
--
Dr. Vera Imper, Ph.D.
Dr. Vera Imper, Ph.D.
Independent Director
Independent Director
15.71K
--
Umsatzaufteilung
Währung: USDAktualisiert: Sun, Jul 6
Währung: USDAktualisiert: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biotechnology, pharmaceutical, distributor and CRO
24.32M
58.68%
Academia and government
17.13M
41.32%
Nach RegionUSD
Name
Umsatz
Anteil
United States
18.54M
44.71%
EMEA
11.57M
27.90%
APAC
8.89M
21.45%
Other
2.46M
5.95%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Biotechnology, pharmaceutical, distributor and CRO
24.32M
58.68%
Academia and government
17.13M
41.32%
Aktionärsstatistik
Aktualisiert: Sat, May 17
Aktualisiert: Sat, May 17
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.03%
The Vanguard Group, Inc.
6.13%
Brown Capital Management, LLC
5.89%
HHLR Advisors, Ltd.
5.26%
Yan (Ming)
4.77%
Other
64.92%
Aktionäre
Aktionäre
Anteil
BlackRock Institutional Trust Company, N.A.
13.03%
The Vanguard Group, Inc.
6.13%
Brown Capital Management, LLC
5.89%
HHLR Advisors, Ltd.
5.26%
Yan (Ming)
4.77%
Other
64.92%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor
32.16%
Investment Advisor/Hedge Fund
19.89%
Individual Investor
9.24%
Hedge Fund
3.64%
Pension Fund
2.67%
Research Firm
1.68%
Bank and Trust
0.36%
Venture Capital
0.13%
Family Office
0.05%
Other
30.18%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
323
88.14M
69.58%
-10.95M
2025Q1
332
90.47M
71.35%
-13.48M
2024Q4
323
90.06M
70.25%
-11.48M
2024Q3
303
87.47M
66.52%
-16.26M
2024Q2
288
88.67M
67.45%
-13.39M
2024Q1
284
98.75M
75.24%
-12.70M
2023Q4
276
96.90M
74.11%
-15.57M
2023Q3
266
97.16M
71.81%
-17.75M
2023Q2
259
98.92M
72.71%
-3.90M
2023Q1
228
90.71M
67.01%
-5.56M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
BlackRock Institutional Trust Company, N.A.
16.50M
13.03%
-335.36K
-1.99%
Mar 31, 2025
The Vanguard Group, Inc.
9.60M
7.58%
-2.09M
-17.92%
Mar 31, 2025
Brown Capital Management, LLC
7.46M
5.89%
-782.64K
-9.49%
Mar 31, 2025
HHLR Advisors, Ltd.
6.66M
5.26%
--
--
Mar 31, 2025
Yan (Ming)
6.04M
4.77%
+10.32K
+0.17%
May 19, 2025
Jiang (Wenbin)
5.26M
4.15%
+36.82K
+0.70%
May 19, 2025
State Street Global Advisors (US)
4.38M
3.46%
-128.20K
-2.84%
Mar 31, 2025
Dimensional Fund Advisors, L.P.
2.85M
2.25%
+1.02M
+55.91%
Mar 31, 2025
Geode Capital Management, L.L.C.
2.69M
2.12%
+47.59K
+1.80%
Mar 31, 2025
New York State Common Retirement Fund
2.09M
1.65%
--
--
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Sat, Aug 2
Aktualisiert: Sat, Aug 2
Name
Anteil
Invesco S&P SmallCap Health Care ETF
0.25%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.06%
SPDR S&P 600 Small Cap Value ETF
0.06%
Avantis US Small Cap Equity ETF
0.05%
iShares S&P Small-Cap 600 Value ETF
0.05%
iShares Biotechnology ETF
0.04%
Proshares Ultra Smallcap 600
0.03%
SPDR Portfolio Small Cap ETF (SPSM)
0.03%
Fidelity Enhanced Small Cap ETF
0.03%
iShares ESG Select Screened S&P Small-Cap ETF
0.03%
Mehr Anzeigen
Invesco S&P SmallCap Health Care ETF
Anteil0.25%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Anteil0.06%
SPDR S&P 600 Small Cap Value ETF
Anteil0.06%
Avantis US Small Cap Equity ETF
Anteil0.05%
iShares S&P Small-Cap 600 Value ETF
Anteil0.05%
iShares Biotechnology ETF
Anteil0.04%
Proshares Ultra Smallcap 600
Anteil0.03%
SPDR Portfolio Small Cap ETF (SPSM)
Anteil0.03%
Fidelity Enhanced Small Cap ETF
Anteil0.03%
iShares ESG Select Screened S&P Small-Cap ETF
Anteil0.03%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
